This study focuses on the potential of Flavin Mononucleotide (FMN) as a biomarker for predicting organ quality and post-transplant outcomes. FMN, released from mitochondrial complex I during reperfusion, indicates the extent of ischemia-reperfusion injury (IRI). The research investigates FMN levels in perfusate samples during normothermic and hypothermic machine perfusion (NMP and HOPE). The study highlights FMN as a reliable tool to assist in organ acceptance decisions and assess graft quality before transplantation.
L. Wang, E. Thompson, L. Bates, T.L. Pither, S.A. Hosgood, M.L. Nicholson, C.J.E. Watson, C. Wilson, A.J. Fisher, S. Ali, J.H. Dark. Transplant Direct. (2020); Aug 21;6(9):e600. doi: 10.1097/TXD.0000000000001046. PMID: 32904032. PMCID: PMC7447496
